Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Alkeon Capital Management Panayotis Takis Sparaggis | 2,241,832 | $104,671,136 | 0.17% | |
| 2. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,774,938 | $82,871,855 | +2% | 2.1% |
| 3. | Suvretta Capital Management Aaron Cowen | 1,676,811 | $78,290,306 | -22% | 2.9% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,466,547 | $68,473,079 | 0.85% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 968,990 | $45,242,142 | -35% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | Officer, Director | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | Officer, Director | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | Officer, Director | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | Large Shareholder, Other | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | Officer | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.98 | 584 | 12,009 | 2024-07-02 | Filing | ||
| $45.00 | 9,806 | 57,981 | 2024-06-12 | Filing | ||
| $41.10 | 1,737 | 7,248 | 2024-06-10 | Filing | ||
| $43.66 | 354 | 48,431 | 2024-05-02 | Filing | ||
| $44.10 | 142 | 48,785 | 2024-04-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,673,432 | $414,763,518 | 0% | |
| 2. | 6,887,086 | $329,340,453 | 5.14% | |
| 3. | 5,238,400 | $250,500,292 | 0% | |
| 4. | 4,415,029 | $211,126,686 | 0.03% | |
| 5. | 4,118,008 | $196,923,143 | 0.59% |
News See All
5 NASDAQ Stocks with Biggest Upside
Based on 12 Wall Street analysts’ ratings in the last three months, Rivian Automotive, Inc. (NASDAQ:RIVN) has a consensus rating of Moderate Buy.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. beats earnings expectations. Reported EPS is $-1.52, expectations were $-1.65. Ultragenyx Pharmaceutical Inc.
15 Best Strong Buy Stocks To Invest In
In this piece, we will take a look at the 15 best strong buy stocks to invest in.
13 Most Promising Future Stocks To Buy According To Hedge Funds
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Billionaire Hedge Funds
